Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers

Data collection

We used routinely collected clinical data from Oxford University Hospitals (OUH) NHS Foundation Trust, a large teaching hospital trust in the South East of the UK, with ~1000 inpatient beds. The data is collected by the local NIHR HIC team in Oxford, being drawn automatically from operational systems into a data warehouse and linked to produce a comprehensive record for each patient, as previously described (17). All of the data used for this studied were provided in anonymised form by OUH NHS Foundation Trust, with the prior approval of the Trust Information Governance Team, following the satisfactory completion of a Data Protection Impact Assessment. The management of the dataset is governed by the NIHR HIC Data Sharing Framework. Research Ethics Committee approval was obtained for the database and associated activity: IRAS ID 174658; REC reference 15/SC/0523.

The data extracted for this study included detailed information on demographics, body mass index (BMI), emergency admissions, blood test results, diagnostic codes, procedures, intensive care unit admission, prescriptions, medicines administration, and discharge destination/outcome for all patients admitted to OUH between 1^st January 2020 and 21^st August 2020.

Inclusion and exclusion criteria

To select eligible data for adults with/without COVID-19, the inclusion criteria were: (a) at least one RT-PCR nose/throat swab having been undertaken (COVID-19 patients were defined by at least one positive result; COVID-19-negative patients were defined by the absence of a positive result); (b) age ≥ 18 years when tested; (c) hospitalised patients; and (d) at least one episode of liver biochemistry recorded at the time of receiving RT-PCR test or after RT-PCR test (the set of liver biochemistry routinely tested by OUH clinical biochemistry laboratory comprises ALT, ALP, albumin, and BR; AST and GGT are not routinely tested). Exclusion criteria were: (a) SARS-CoV-2 RT-PCR test results reported as invalid; (b) missing age; and (c) pregnancy (antenatal/delivery/post-partum).

Definitions

We defined baseline as the date of the first positive SARS-CoV-2 RT-PCR test for a COVID-19 patient and the date of the first negative test for a patient without COVID-19. The end of follow-up was defined as the date of last available electronic patient record data for a patient.

The normal ranges set by the hospital biochemistry lab are: ALT: 10-45 IU/L; ALP: 30-130 IU/L; BR: 0-21 umol/L; Albumin: 32-50 g/L. The reference ranges for other blood tests are provided in Table S1. We defined baseline liver biochemistry (ALT, ALP, BR, or albumin) as the liver biochemistry measured within 7 days of SARS-CoV-2 RT-PCR test and baseline derangement as at least one abnormal result at this time point. We defined peak/nadir liver biochemistry derangement as at least one abnormal value at any point during follow-up. We defined liver biochemistry recovery as normalisation following derangement. The primary outcome was death during follow-up, and secondary outcomes included ICU admission and invasive ventilation.

Pre-existing comorbidities were defined by a historical diagnosis of a disease before baseline, and diagnosis codes retrieved were provided in Table S2. A full list of prescribed drugs searched for data extraction is provided in Table S3.

Statistical analysis

Statistical analysis was performed using R version 4.0.2. All significance tests performed were two-sided. p values <0.05 were deemed statistically significant.

Identification, demographics, and outcomes of COVID-19 compared to non-COVID-19 groups

We identified 6311 eligible patients (585 adults with SARS-CoV-2 infection and 5726 without) according to the inclusion/exclusion criteria (Figure S1). Based on our 585 COVID-19-positive patients, we matched a cohort of 1165 COVID-19-negative patients. After matching, there were no significant differences in demographics and pre-existing comorbidities between the two groups (Table 1; Table S4). Median duration of follow-up was 58 [IQR: 14-104] days in the COVID-19 group and 50 [IQR: 20-78] days in the matched non-COVID-19 group, with no difference in the monitoring duration of liver biochemistry (Table 1). The distribution of admitting specialties (Table S5) and prescribed antiviral therapy did not differ significantly between COVID-19 and non-COVID-19 groups (Table S6).

Over a median follow-up of 58 days vs. 50 days, 26.8% (157/585) of COVID-19 patients died compared to 11.9% (139/1165) in the non-COVID-19 group (p<0.001), respectively. The COVID-19 group had a higher rate of ICU admission during hospitalisation (12.1% vs. 4.3%, p<0.001), and a higher rate of invasive ventilation use in ICU (8% vs. 2.5%, p<0.001) (Table 1). The K-M estimated probability of surviving beyond 30 days after SARS-CoV-2 RT-PCR test was 77% for COVID-19 patients compared to 92% for non-COVID-19 patients (Figure 1).

• Download figure
• Open in new tab

Figure 1. K-M curves for the comparison of time to death in COVID-19 group vs. non-COVID-19 group since SARS-CoV-2 RT-PCR test

One in COVID-19 group has missing death date. p-value was based on the logrank test.

Assessment of liver biochemistry in the COVID-19 compared to non-COVID-19 group

Baseline liver biochemistry was available in 492 COVID-19 patients and 974 non-COVID-19 patients; patients with deranged peak liver biochemistry were less likely to have missing baseline liver biochemistry data (Table S7). The median time interval between consecutive liver biochemistry measurements was 1 [IQR: 1-4] day and 2 [IQR: 1-7] days, for COVID-19 and non-COVID-19 groups respectively.

At baseline, the COVID-19 group had a significantly higher median ALT value (25 IU/L vs. 19 IU/L, p<0.001) and a higher proportion of patients with ALT >ULN (20.7% vs.14.6%, p=0.004) than the non-COVID-19 group. The COVID-19 group also had a lower median albumin (30 g/L vs. 34 g/L, p<0.001), lower platelets (216 x10*9/L vs. 245 x10*9/L, p<0.001), lower lymphocytes (0.9 x10*9/L vs. 1.2 x10*9/L, p<0.001) and a significantly higher CRP (78 mg/L vs. 20 mg/L, p<0.001), as compared to the non-COVID-19 group. Activated partial thromboplastin time (APPT) and baseline vital signs were also more deranged in the COVID-19 group, whilst renal function was preserved (Table 1). Overall, the COVID-19 group had a significantly higher proportion of patients with ≥1 deranged liver biochemistry at baseline compared to the non-COVID-19 group (72.6% vs. 55.5%, p<0.001) (Table S8).

Over follow-up, the COVID-19 group also had more deranged liver biochemistry, with a higher median peak ALT (34 IU/L vs. 26 IU/L, p<0.001), a higher proportion with peak ALT >ULN (37.9% vs. 27.7%, p<0.001), a lower median nadir albumin (26 g/L vs. 29 g/L, p<0.001), and a higher prevalence of hypoalbuminaemia (79.0% vs. 59.5%, p<0.001) compared to the non-COVID-19 group (Table S8). COVID-19 patients also had significantly higher median ALT and lower median albumin values at all time points throughout follow-up (7, 14, 21, and 28 days), compared to the non-COVID-19 group (all p<0.05) (Figure 2A-B). In the COVID-19 group, median ALT increased at 7 and 14 days, compared to baseline (both p<0.05) (Figure 2C), and median albumin decreased at 7 days of follow-up compared to baseline (p<0.0001) and maintained at low levels at subsequent time points (Figure 2D). We did not identify differences in ALP and bilirubin over time between these groups, other than at baseline or at 7 days (Figure S2).

• Download figure
• Open in new tab

Figure 2.

Comparison of ALT and albumin between hospitalised adults with COVID-19 and non-COVID-19 patients matched for age, gender, ethnicity and pre-existing comorbidities (A) ALT comparison at baseline, and 7, 14, 21, 28 days; (B) Albumin comparison at baseline, and 7, 14, 21, 28 days; (C) ALT changes over time in COVID-19 and non-COVID-19 groups; (D) Albumin changes over time in COVID-19 and non-COVID-19 groups. ALT, Alanine transaminase. Green dash-dotted lines indicate the lower limits of normal and the upper limits of normal. * p-value <0.05, ** p-value <0.01, *** p-value <0.001, **** p-value <0.0001.

Demographics, comorbidities and liver biochemical characteristics associated with mortality in COVID-19 patients

In the COVID-19 group, patients who died were significantly older than those who survived (median age 82 years vs. 66 years respectively), significantly more likely to have pre-existing comorbidities including liver disease, DM, CHD and cancer (Table 2), significantly more likely to have baseline hypoalbuminaemia (72.6% vs. 52.9%, p<0.001) and low nadir albumin during follow-up (96.2% vs. 72.7%, p<0.001, Table 2). In patients who died, baseline ALP was higher (p=0.007) and peak BR was more likely to be abnormal compared to those who survived (p=0.016, Table S9). Prescribed antiviral drug use was not different between groups (Table S9). Equivalent data for the non-COVID-19 group are provided in Table S10.

Survival curves and logrank tests (unadjusted for relevant confounders) within the COVID-19 group displayed that surviving probability over time was significantly lower in patients with hypoalbuminaemia at baseline than those with normal baseline albumin (Figure 3A), a higher surviving probability in patients with elevated baseline ALT as compared to normal baseline ALT (Figure 3B), while elevated ALP or bilirubin at baseline were not significantly associated with a lower survival probability over time (Figure 3C-D). In addition, for the subset of COVID-19 patients who had prothrombin time (PT) and international normalised ratio (INR), elevation of these parameters at baseline were significantly associated with a lower survival probability (Figure S3).

• Download figure
• Open in new tab

Figure 3. Survival K-M curves stratified by baseline liver biochemistry at the time of testing positive for SARS-CoV-2

(A) normal and low baseline albumin; (B) normal and elevated baseline ALT; (C) normal and elevated baseline ALP; (D) normal and elevated baseline bilirubin. K-M, Kaplan-Meier. p-values were based on the logrank test. One patient has missing death date.

In multivariate analysis (fully adjusted for demographics, comorbidities, and prescribed drug use before baseline) for the COVID-19 group, those with hypoalbuminaemia at baseline had a 1.83-fold-increased hazards of death compared to those with normal baseline albumin (adjusted HR 1.83, 95% CI 1.25-2.67), those aged ≥75 years had a ~4-fold-increased hazards of death compared to those aged <75 years (adjusted HR 3.96, 95% CI 2.59-6.04), and those with pre-existing liver disease had a ~3-fold-increased hazards of death than those without pre-existing liver disease (adjust HR 3.37, 95% CI 1.58-7.16) (Table 3). More specifically, a one unit (1 g/L) decrease in albumin at baseline was associated with a 5% increase in hazards of death (adjusted HR 1.05, 95%CI 1.02-1.09), while age increased by 10 years was associated with 82% increase in hazards of death (adjusted HR 1.82, 95% CI 1.56-2.13) (Table S11). Similarly, a one unit decrease in nadir albumin during follow-up was associated with a 7% increase in hazards of death (adjusted HR 1.07, 95% CI 1.04-1.10) (Table S12). In the COVID-19 group baseline albumin was significantly negatively correlated with age in those that survived (R=-0.264, p<0.0001) but not in those who died (R=-0.027, p=0.75) (Figure S4).

For the subset of COVID-19 patients who had BMI data (survived vs. died, 246 vs. 96), HRs did not change materially after additional adjustment for BMI in the multivariate analysis (Table S13). Baseline albumin was weakly correlated with BMI both in those who died and survived (R=0.08, p=0.42 vs. R=0.099, p=0.12, respectively) (Figure S5).

Longitudinal assessment of liver biochemistry patterns in patients who died with COVID-19, compared to those who survived

Within the COVID-19 group, patients who died during follow-up had significantly lower median values of albumin at baseline, 7 and 14 days after a positive SARS-CoV-2 RT-PCR, compared to the patients who survived (all p<0.001) (Figure 4A). There was no significant difference in ALT at any time point other than 7 days between those who died and survived (Figure 4B), while ALP was higher at baseline and 28 days (both p<0.05) and BR was higher at 7 days (p<0.05) (Figure 4C-D).

• Download figure
• Open in new tab

Figure 4. Comparison of liver biochemistry between patients with COVID-19 who died during follow-up and who survived to the end of follow-up

(A) Albumin comparison at baseline at baseline, 7, 14, 21, 28 days; (B) ALT comparison at baseline, 7, 14, 21, 28 days; (C) ALP comparison at baseline at baseline, 7, 14, 21, 28 days; (D) Bilirubin comparison at baseline at baseline, 7, 14, 21, 28 days. ALT, Alanine transaminase; ALP, Alkaline phosphatase. Green dash-dotted lines indicate the lower limits of normal and the upper limits of normal. * p-value <0.05, ** p-value <0.01, *** p-value <0.001, ****p-value <0.0001.

In the COVID-19 group, ALT increased during the first two weeks and remained elevated during follow-up in patients who died, whilst in patients who survived ALT decreased from 7 days onward with a trend to normalisation (Figure 5A-B). ALP increased over time in both subgroups, with a greater increase in those who died (Figure 5C-D). BR decreased throughout follow-up in both subgroups (Figure 5E-F). Albumin decreased significantly in both groups during the first 7 days and continued to decline in patients who died, but in patients who survived had an upward trend especially for those had been followed up longer than one month (Figure 5G-H).

• Download figure
• Open in new tab

Figure 5. Longitudinal changes of liver biochemistry over time of COVID-19 patients stratified by death during follow-up

(A) ALT at baseline, 7, 14, 21, 28 days; (B) Changing trend over time (112 vs. 155 days) of ALT by linear regression line fitting with 95% CI; (C) ALP at baseline at baseline, 7, 14, 21, 28 days; (D) Changing trend over time (112 vs. 155 days) of ALP by linear regression line fitting with 95% CI; (E) Bilirubin at baseline at baseline, 7, 14, 21, 28 days; (F) Changing trend over time (112 vs. 155 days) of bilirubin by linear regression line fitting with 95% CI; (G) Albumin at baseline at baseline, 7, 14, 21, 28 days; (H) Changing trend over time (112 vs. 155 days) of albumin by linear regression line fitting with 95% CI. ALT, Alanine transaminase; ALP, Alkaline phosphatase; CI, Confidence interval. Green dash-dotted lines indicate the lower limits of normal and the upper limits of normal. * p-value <0.05, ** p-value <0.01, *** p-value <0.001, **** p-value <0.0001. R represents Pearson’s correlation coefficient and p indicates linear regression significance.

Among COVID-19 patients who had ≥2 longitudinal data points for ALT, ALP, BR and albumin, 468 had at least one liver biochemistry derangement during follow-up. Among them 26.9% (126/468) had normalised by the end of follow-up, while the remaining 73.1% still had at ≥1 abnormal liver biochemistry at the end of follow-up. The information of each liver biochemistry recovery were provided in Table S14.

Novelty and key findings

To our knowledge this is the first study to: i) comprehensively conduct longitudinal analyses of liver biochemistry patterns over time in COVID-19 patients compared to a matched general patient cohort, and ii) analyse longitudinal liver biochemistry patterns in COVID-19 patients who have died and survived. We have gathered a large cohort through an automatic approach, and account for missing data in the analysis.

The COVID-19 group exhibited ~2-fold higher death rate, with significantly lower survival probability compared to the non-COVID-19 group. Among the COVID-19 group, a higher proportion of patients had at least one abnormal liver biochemistry (ALT, ALP, BR or albumin) at baseline and during follow-up, compared to the matched non-COVID-19 group. Patients with COVID-19 who died showed a decline in albumin and a greater increase in ALP over time compared to those who survived, and baseline hypoalbuminaemia was a significant predictor of death in COVID-19 patients on multivariate analysis with adjusting for relevant confounders.

Comparison to previous studies

In our study, rates of baseline and peak ALT derangement between COVID-19 and non-COVID-19 groups were significantly different, consistent with findings from a large USA cohort (8). The increase in ALT between baseline and at 14 days follow-up in the COVID-19 group is also consistent with previous research (6).

Patients with pre-existing liver disease were found to have an increased risk of mortality in COVID-19 which is consistent with the findings of previous studies (19, 20) however there is only a small number of patients with the pre-existing liver disease in our study. Because some COVID-19 patients in our cohort were admitted to hospital for non-COVID-19 we analysed baseline liver biochemistry at the time of the SARS-CoV-2 RT-PCR rather than date of admission. This may partially explain differences between our study and previous studies which analysed liver biochemistry measured on hospital admission (3-6). Variable patterns of drug use between cohorts may also account for differences.

Although baseline hypoalbuminaemia was significantly associated with hazards of death in COVID-19, ALT, ALP, and BR were not. Recent findings from two multi-centre studies support the prognostic association of albumin with death in COVID-19 (16, 21). However, other studies aiming to explore whether liver biochemistry derangement is associated with death in COVID-19 did not investigate albumin (6-8). Interestingly, a previous study found that hypoalbuminemia is a strong predictor of 30-day all-cause mortality in acutely admitted medical patients (22). As albumin is a cheap and widely available test, it can be usefully employed as a prognostic biomarker.

Due to variable population settings in previous studies (e.g., demographics, comorbidities), it is important to understand the populations in which prognostic models are developed (12) to ensure such models are externally valid. For example, a study from the US (8) reported a positive association of ALT >5 times ULN with death, however we were unable to replicate this investigation as only a small number of participants had ALT elevated to this level; furthermore, the prevalence of comorbid disease and BMI >35kg/m² in the US study population was much higher compared to our cohort. Similarly, a large primary care cohort study (23) reported that BMI >40kg/m² was associated with an increased risk of COVID-19-related death, but we were underpowered to replicate this analysis.

COVID-19 and liver biochemistry derangement

Although derangements in liver biochemistry are common in COVID-19 patients, the reasons for the liver injury remain unclear, but may include direct viral damage, drug-induced liver injury, hypoxia, immune-mediated injury, sepsis, or cytokine release (24, 25). Angiotensin-converting enzyme 2 (ACE2), a functional receptor for SARS-CoV-2 (26) is found abundantly in the gastrointestinal tract and liver, in addition to presenting in alveolar type 2 cells (the major SARS-CoV-2 targeting cell type in lung). A recent study observed a higher expression of ACE2 in cholangiocytes (59.7% of cells) compared to hepatocytes (2.6%) (27). Given the hepatic distribution of the ACE2 receptor, SARS-CoV-2 may well cause damage of both bile ducts and liver (28, 29). Alternatively, the liver may be a bystander, with deranged liver biochemistry reflecting systemic disease (30).

Caveats and limitations

Routinely collected liver biochemistry is not consistent between settings, and therefore the definitions of liver biochemistry derangement may vary across studies. Although AST and GGT have been investigated in previous studies, these parameters are not available for our population. We recognise that analysis can be influenced by missing data, but we report missing values and investigating peak/nadir values as well as baseline. We also undertook sensitivity analysis in a subset of patients with complete BMI measurements to investigate its association with death. Our cohort in the South East of the UK may not be representative of populations elsewhere, especially in terms of ethnic diversity, so caution should be applied in extrapolation of results.

Future studies

Further longitudinal studies of COVID-19 outcomes in diverse patient groups, including those with pre-existing liver disease are needed. The NIHR HIC program will continue to benefit the field of COVID-19 research, as data accumulated for further large teaching hospitals can be used to expand this analysis, resulting in a more generalizable study population and increased statistical power.

Conclusion

Liver biochemistry derangement is common in COVID-19 patients at the time of a SARS-CoV-2 RT-PCR test and during the clinical course of disease. Baseline and nadir albumin are valuable prognostic factors that are associated with death in COVID-19 patients.